SE459228B - Anvaendning av en blandning av en lysofosfolipid och en fosfolipid foer framstaellning av en karcinostatisk och immunstimulerande beredning samt foerfarande foer framstaellning av beredningen - Google Patents
Anvaendning av en blandning av en lysofosfolipid och en fosfolipid foer framstaellning av en karcinostatisk och immunstimulerande beredning samt foerfarande foer framstaellning av beredningenInfo
- Publication number
- SE459228B SE459228B SE8001685A SE8001685A SE459228B SE 459228 B SE459228 B SE 459228B SE 8001685 A SE8001685 A SE 8001685A SE 8001685 A SE8001685 A SE 8001685A SE 459228 B SE459228 B SE 459228B
- Authority
- SE
- Sweden
- Prior art keywords
- phospholipid
- lysophospholipid
- preparation
- mixture
- use according
- Prior art date
Links
- 150000003904 phospholipids Chemical class 0.000 title claims description 39
- 239000000203 mixture Substances 0.000 title claims description 34
- 230000003327 cancerostatic effect Effects 0.000 title claims description 23
- 238000002360 preparation method Methods 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 18
- 239000006185 dispersion Substances 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 20
- 230000003308 immunostimulating effect Effects 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 15
- 239000000644 isotonic solution Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- -1 sphingomyelin Chemical compound 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 239000012265 solid product Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 239000002960 lipid emulsion Substances 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000011521 glass Substances 0.000 description 15
- 239000011324 bead Substances 0.000 description 14
- 239000003925 fat Substances 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 238000010253 intravenous injection Methods 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000009210 therapy by ultrasound Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000004821 distillation Methods 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000008344 egg yolk phospholipid Substances 0.000 description 6
- 229940068998 egg yolk phospholipid Drugs 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003549 soybean oil Substances 0.000 description 6
- 235000012424 soybean oil Nutrition 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009950 felting Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2460079A JPS55118419A (en) | 1979-03-05 | 1979-03-05 | Antihemolytic composition consisting of fat emulsion and immunizator and carcinostatic agent containing the same |
| JP11726279A JPS5840929B2 (ja) | 1979-09-14 | 1979-09-14 | リゾレシチンおよびリン脂質を含有する制癌剤およびその製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8001685L SE8001685L (sv) | 1980-10-20 |
| SE459228B true SE459228B (sv) | 1989-06-19 |
Family
ID=26362150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8001685A SE459228B (sv) | 1979-03-05 | 1980-03-04 | Anvaendning av en blandning av en lysofosfolipid och en fosfolipid foer framstaellning av en karcinostatisk och immunstimulerande beredning samt foerfarande foer framstaellning av beredningen |
Country Status (8)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3127503A1 (de) * | 1981-07-11 | 1983-02-17 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| IL63734A (en) * | 1981-09-04 | 1985-07-31 | Yeda Res & Dev | Lipid fraction,its preparation and pharmaceutical compositions containing same |
| US4578391A (en) * | 1982-01-20 | 1986-03-25 | Yamanouchi Pharmaceutical Co., Ltd. | Oily compositions of antitumor drugs |
| US4452747A (en) * | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
| US5334583A (en) * | 1982-07-23 | 1994-08-02 | Ciba-Geigy Corp. | Use of sugar derivatives for the prophylaxis and treatment of virus infections |
| US5189017A (en) * | 1982-07-23 | 1993-02-23 | Ciba-Geigy Corporation | Use of sugar derivatives for the prophylaxis and treatment of virus infections |
| US5059591B1 (en) * | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
| CA1237670A (en) * | 1983-05-26 | 1988-06-07 | Andrew S. Janoff | Drug preparations of reduced toxicity |
| IL72420A (en) * | 1983-07-22 | 1987-10-30 | Hoffmann La Roche | Aqueous vitamin e solutions and their manufacture |
| JPS6045518A (ja) * | 1983-08-22 | 1985-03-12 | Takeda Chem Ind Ltd | 抗シヨツク剤 |
| US4873088A (en) * | 1983-09-06 | 1989-10-10 | Liposome Technology, Inc. | Liposome drug delivery method and composition |
| JPS6081193A (ja) * | 1983-10-11 | 1985-05-09 | Takeda Chem Ind Ltd | リン脂質 |
| JPS60208910A (ja) * | 1984-03-31 | 1985-10-21 | Green Cross Corp:The | 水難溶性薬物・リン脂質複合体の製造方法 |
| PT78628B (en) * | 1984-05-02 | 1986-06-18 | Liposome Co Inc | Pharmaceutical composition with reduced toxicity |
| DE3421468A1 (de) * | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
| DE3572491D1 (en) * | 1984-07-25 | 1989-09-28 | Ciba Geigy Ag | Phosphatidyl compounds, process for their preparation and their use |
| US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4921706A (en) * | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
| US4622188A (en) * | 1984-12-21 | 1986-11-11 | E. I. Du Pont De Nemours And Company | Method for manufacturing liposomes |
| US4737276A (en) * | 1984-12-21 | 1988-04-12 | E. I. Du Pont De Nemours And Company | Apparatus for manufacturing liposomes |
| US5409704A (en) * | 1985-06-26 | 1995-04-25 | The Liposome Company, Inc. | Liposomes comprising aminoglycoside phosphates and methods of production and use |
| US4916249A (en) * | 1985-07-03 | 1990-04-10 | Hans Brachwitz | Glycero-3(2)-phospho-L-serine derivatives and salts thereof |
| US4857514A (en) * | 1985-09-17 | 1989-08-15 | Yeda Research And Development Company, Ltd. | Virus inactivation |
| EP0244456B1 (en) * | 1985-10-21 | 1992-01-15 | The Liposome Company, Inc. | In situ preparation and delivery of liposomes |
| US4923854A (en) * | 1986-01-22 | 1990-05-08 | The Liposome Company, Inc. | Solubilization of hydrophobic materials using lysophospholipid |
| US4873322A (en) * | 1986-01-24 | 1989-10-10 | Ciba-Geigy Corporation | Saccharide derivatives and processes for their manufacture |
| US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4971801A (en) * | 1986-06-09 | 1990-11-20 | Cell Technology, Inc. | Biologic response modifier |
| US5009956A (en) * | 1987-02-24 | 1991-04-23 | Univ Minnesota | Phospholipase A2-resistant liposomes |
| MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| WO1988007850A1 (en) * | 1987-04-16 | 1988-10-20 | The Liposome Company, Inc. | Liposome continuous size reduction method and apparatus |
| US5145844A (en) * | 1987-07-23 | 1992-09-08 | Hoechst-Roussel Pharmaceuticals Incorporated | Methods of using hydroxy-, alkoxy- and benzyloxy-substituted phospholipids to treat phospholipase A2 -mediated conditions and to alleviate pain |
| US5030733A (en) * | 1987-07-23 | 1991-07-09 | Hoechst-Roussel Pharmaceticals Incorporated | Hydroxy-, alkoxy- and benzyloxy-substituted phospholipids |
| US4978332A (en) * | 1987-09-28 | 1990-12-18 | Matrix Pharmaceutical, Inc. | Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas |
| US5185334A (en) * | 1989-07-31 | 1993-02-09 | Schering Corporation | 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use |
| US4888328A (en) * | 1988-03-10 | 1989-12-19 | Hoeschst-Roussel Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| US5036152A (en) * | 1988-03-10 | 1991-07-30 | Hoechst-Roussel Pharmaceuticals Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| US5230900A (en) * | 1988-07-01 | 1993-07-27 | The Biomembrane Institute | Antibody-mediated and ligand-mediated targeting of differentiation-inducers to tumor cells |
| JPH02184633A (ja) * | 1988-11-23 | 1990-07-19 | Abbott Lab | エイズ治療剤 |
| DE3906952A1 (de) * | 1989-03-04 | 1990-09-06 | Boehringer Mannheim Gmbh | (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel |
| US5100662A (en) * | 1989-08-23 | 1992-03-31 | The Liposome Company, Inc. | Steroidal liposomes exhibiting enhanced stability |
| ATE138803T1 (de) * | 1990-07-31 | 1996-06-15 | Liposome Co Inc | Anhäufung von aminosäuren und peptiden in liposomen |
| WO1992008448A1 (en) * | 1990-11-09 | 1992-05-29 | Cell Technology, Inc. | Method for preventing drug-induced or radiation myelosuppression |
| US5620703A (en) * | 1991-10-11 | 1997-04-15 | Max-Delbruck-Centrum Fur Molekulare Medizin | Stimulating hematopoietic activity with carboplatin or lobaplatin |
| US5817646A (en) * | 1991-11-15 | 1998-10-06 | Laboratoires Inocosm | Polar lipid composition of plant origin |
| IT1255476B (it) * | 1992-07-30 | 1995-11-02 | Glicerofosfoderivati farmacologicamente attivi | |
| DE69432930T2 (de) | 1993-09-09 | 2004-05-06 | Lorus Therapeutics Inc., Toronto | Immunmodulierende zusammensetzungen aus galle |
| US6551623B1 (en) | 1993-09-09 | 2003-04-22 | Lorus Therapeutics Inc. | Immunomodulating compositions from bile |
| US5707978A (en) * | 1994-11-22 | 1998-01-13 | Clarion Pharmaceuticals Inc. | Heteroaryl-substituted deoxy glycero-phosphoethanolamines |
| NZ302638A (en) | 1995-03-16 | 2001-04-27 | Imutec Pharma Inc | Immunomodulating composition from bile for the treatment of immune system disorders |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| US5665714A (en) * | 1995-12-07 | 1997-09-09 | Clarion Pharmaceuticals Inc. | N-substituted glycerophosphoethanolamines |
| US5730157A (en) * | 1995-12-07 | 1998-03-24 | Clarion Pharmaceuticals Inc. | Method for treating viral infection |
| US5703062A (en) * | 1995-12-07 | 1997-12-30 | Clarion Pharmaceuticals Inc. | N-het-substituted glycerophosphoethanolamines |
| BRPI9708566B8 (pt) | 1996-04-12 | 2022-01-18 | Ontario Inc 1149336 | análogo de glp-2 de mamífero, e, composição farmacêutica. |
| US20040101569A1 (en) * | 1996-05-16 | 2004-05-27 | Lorus Therapeutics Inc. | Immunomodulating compositions from bile |
| US6111081A (en) * | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
| US5932242A (en) * | 1996-10-15 | 1999-08-03 | The Liposome Company, Inc. | Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof |
| US6037125A (en) * | 1996-11-05 | 2000-03-14 | Lexicon Genetics Incorporated | Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells |
| US5827836A (en) * | 1996-11-15 | 1998-10-27 | Clarion Pharmaceuticals Inc. | Retinoid glycerol phospholipid conjugates |
| CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| GB9906695D0 (en) * | 1999-03-24 | 1999-05-19 | Secr Defence | Vaccine composition |
| US20020001614A1 (en) * | 2000-02-10 | 2002-01-03 | Kent Jorgensen | Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof |
| CA2477982A1 (en) * | 2002-03-05 | 2003-09-18 | Transave, Inc. | Methods for entrapment of bioactive agent in a liposome or lipid complex |
| US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| MXPA05004580A (es) * | 2002-10-29 | 2005-07-26 | Transave Inc | Liberacion sostenida de anti - infecciosos. |
| US20060078560A1 (en) * | 2003-06-23 | 2006-04-13 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| JP2008516899A (ja) * | 2004-10-15 | 2008-05-22 | ビオファーマコペ デジン アンテルナショナル インク． | 癌治療のための植物抽出物から成る方法および成分 |
| EP1745788A1 (de) | 2005-07-22 | 2007-01-24 | KTB Tumorforschungsgesellschaft mbH | Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie |
| ES2594368T3 (es) | 2005-12-08 | 2016-12-19 | Insmed Incorporated | Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares |
| WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
| CN101358609A (zh) * | 2007-08-03 | 2009-02-04 | 富准精密工业(深圳)有限公司 | 风扇转子 |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
| EP2852391B1 (en) | 2012-05-21 | 2021-11-17 | Insmed Incorporated | Systems for treating pulmonary infections |
| EP2925298B1 (en) | 2012-11-29 | 2019-05-29 | Insmed Incorporated | Stabilized vancomycin formulations |
| KR101951933B1 (ko) * | 2013-03-12 | 2019-02-25 | 주식회사 아리바이오 | 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법 |
| WO2015006228A1 (en) | 2013-07-08 | 2015-01-15 | The University Of Utah Research Foundation | Methods for treatment of and prophylaxis against inflammatory disorders |
| EP3135297A4 (en) * | 2014-04-04 | 2018-02-07 | Osaka University | Drug delivery promoter containing substance for activating lysophospholipid receptors |
| EP4393491A3 (en) | 2014-05-15 | 2024-07-24 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
| EP3357512A4 (en) * | 2015-09-29 | 2019-05-29 | Osaka University | PROMOTER OF LEUKOCYTE INFILTRATION AND TUMORIMMUNACTIVATOR |
| CZ308596B6 (cs) | 2017-04-03 | 2020-12-23 | Ústav molekulární genetiky AV ČR, v. v. i. | Deriváty fosfolipidů a jejich použití jako léčiva |
| WO2018204918A1 (en) | 2017-05-05 | 2018-11-08 | Ardelyx, Inc. | Treatment of hepatic disorders |
| JP7460534B2 (ja) | 2018-03-30 | 2024-04-02 | インスメッド インコーポレイテッド | リポソーム医薬品の連続製造方法 |
| EP3895709A1 (de) | 2020-04-17 | 2021-10-20 | Andreas Hettich GmbH & Co. KG | Phospholipide und phospholipid-metaboliten zur behandlung von viralen und bakteriellen lungenentzündungen und sepsis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2009342C3 (de) * | 1970-02-27 | 1980-12-18 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern |
| DE2009343C3 (de) * | 1970-02-27 | 1980-10-23 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Verwendung von Lysolecithinen als immunologische Adjuvantien |
| US4119714A (en) * | 1970-02-27 | 1978-10-10 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. | Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens |
| DE2009341C3 (de) * | 1970-02-27 | 1979-06-21 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung |
| FR2287901A1 (fr) | 1974-10-14 | 1976-05-14 | Pasteur Institut | Medicament immunostimulant contenant un derive d'ose ou de polyose phosphoryle |
| JPS5186117A (en) * | 1975-01-27 | 1976-07-28 | Tanabe Seiyaku Co | Johoseibiryushiseizainoseiho |
| DE2619686C2 (de) | 1976-05-04 | 1986-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Verwendung eines Lysolecithins zur Tumorbehandlung |
-
1980
- 1980-02-27 GB GB8006531A patent/GB2046092B/en not_active Expired
- 1980-02-29 US US06/125,800 patent/US4372949A/en not_active Expired - Lifetime
- 1980-03-03 DE DE19803008082 patent/DE3008082A1/de active Granted
- 1980-03-03 FR FR8004736A patent/FR2450608A1/fr active Granted
- 1980-03-04 NL NL8001292A patent/NL8001292A/nl not_active Application Discontinuation
- 1980-03-04 CA CA000346889A patent/CA1145260A/en not_active Expired
- 1980-03-04 SE SE8001685A patent/SE459228B/sv not_active IP Right Cessation
- 1980-03-04 IT IT48066/80A patent/IT1145357B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| FR2450608B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-12-21 |
| GB2046092A (en) | 1980-11-12 |
| SE8001685L (sv) | 1980-10-20 |
| IT8048066A0 (it) | 1980-03-04 |
| CA1145260A (en) | 1983-04-26 |
| GB2046092B (en) | 1983-11-02 |
| DE3008082C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-02-11 |
| FR2450608A1 (fr) | 1980-10-03 |
| IT1145357B (it) | 1986-11-05 |
| DE3008082A1 (de) | 1980-09-18 |
| NL8001292A (nl) | 1980-09-09 |
| US4372949A (en) | 1983-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE459228B (sv) | Anvaendning av en blandning av en lysofosfolipid och en fosfolipid foer framstaellning av en karcinostatisk och immunstimulerande beredning samt foerfarande foer framstaellning av beredningen | |
| CN1097458C (zh) | 含有紫杉碱(紫杉醇)的稳定水包油乳剂及其制备方法 | |
| US5364632A (en) | Medicinal emulsions | |
| HUT74423A (en) | Pharmaceutical basic compositions | |
| EP0391369B1 (en) | Medicinal emulsions | |
| US5043164A (en) | Blood-stable, cholesterol-free liposomes | |
| FI70137C (fi) | Foerfarande foer framstaellning av en stabil fettemulsion foer intravenoes injektion. | |
| JP2666345B2 (ja) | リポソーム製剤およびその製造法 | |
| US4308166A (en) | Process for the extemporaneous preparation of liposomes | |
| JP2756526B2 (ja) | リポソーム懸濁液の安定化法及びリポソーム懸濁液 | |
| DE69521693T2 (de) | Taxanderivate enthaltende arzneizubereitungen | |
| HU203278B (en) | Process for producing compositions containing liposomes | |
| JPH0347527A (ja) | 水相中に油粒子のナノエマルジヨンを製造する方法、薬学および化粧品調剤の製法および細胞培養用栄養溶液の製法 | |
| DE3512926A1 (de) | Verbesserung in oder bezueglich der therapie mit interleukin | |
| JPS63112512A (ja) | リポソ−ム製剤およびその製造法 | |
| WO2017168435A1 (en) | Viscoelastic gel of liraglutide adapted for once-weekly or once bi-weekly administration | |
| Daemen et al. | Activity of synthetic phospholipids in blood coagulation | |
| US3044931A (en) | Aryloxy acetic acid amides: process for parenteral application | |
| JPH07108166A (ja) | リポソーム | |
| RU2223764C1 (ru) | Способ получения липосомальной формы рифампицина | |
| WO1992008467A1 (en) | Dispersion preparation | |
| EP0598116B1 (en) | Fat emulsion | |
| BE882048A (fr) | Agent carcinostatique et immunostimulant contenant un lysophospholipide et un phospholipide et procede pour le preparer | |
| JPS6350330B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS63500456A (ja) | 薬剤に用いるミクロエマルジョン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8001685-0 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8001685-0 Format of ref document f/p: F |